Biohaven’s Nurtec Receives the US FDA’s Approval for Treatment of Migraine in Adults

Shots:

• The approval is based on P-III study (Study 303) and Study 201 which involves assessing of Nurtec vs PBO in patients with migraine
• The study resulted in well-tolerated results. Additionally, Biohaven launched a broad suite
• Nurtec (rimegepant, 75mg) is a first and only calcitonin gene-related peptide (CGRP) receptor antagonist approved by the US FDA to treat migraine in adults

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox